Rhenman & Partners Asset Management Ab Increased Portola Pharmaceuticals Inc (NASDAQ:PTLA) Stake by $10.08 Million

October 13, 2017 - By Marguerite Chambers

Investors sentiment decreased to 1.31 in 2017 Q2. Its down 0.29, from 1.6 in 2017Q1. It turned negative, as 17 investors sold PTLA shares while 58 reduced holdings. 45 funds opened positions while 53 raised stakes. 48.64 million shares or 0.79% more from 48.26 million shares in 2017Q1 were reported. First Mercantile accumulated 0.08% or 7,500 shares. Huntington Commercial Bank holds 0% or 40 shares in its portfolio. Hanseatic Services reported 0.65% stake. Raymond James Financial Services Advisors holds 4,408 shares or 0% of its portfolio. Howe And Rusling stated it has 1,100 shares. 16,419 were reported by Tudor Investment Corporation Et Al. State Street Corp owns 2.09 million shares. Wexford Lp holds 6,600 shares. Prudential Finance accumulated 0.01% or 90,136 shares. Ny State Common Retirement Fund stated it has 69,786 shares. Ubs Asset Mngmt Americas Incorporated stated it has 276,067 shares or 0% of all its holdings. Loring Wolcott & Coolidge Fiduciary Advisors Llp Ma stated it has 10 shares or 0% of all its holdings. Fernwood Mngmt Ltd owns 238,877 shares for 9.73% of their portfolio. Jpmorgan Chase And, New York-based fund reported 718,158 shares. Renaissance Techs Ltd holds 0.03% in Portola Pharmaceuticals Inc (NASDAQ:PTLA) or 377,200 shares.

Since May 31, 2017, it had 1 buying transaction, and 1 sale for $54.68 million activity. Shares for $58.48M were sold by Maxwell (Mauritius) Pte Ltd on Thursday, June 1.

Rhenman & Partners Asset Management Ab increased its stake in Portola Pharmaceuticals Inc (NASDAQ:PTLA) by 168.4% based on its latest 2017Q3 regulatory filing with the SEC. Rhenman & Partners Asset Management Ab bought 186,595 shares as the company’s stock rose 22.73% with the market. The institutional investor held 297,400 shares of the health care company at the end of 2017Q3, valued at $16.07M, up from 110,805 at the end of the previous reported quarter. Rhenman & Partners Asset Management Ab who had been investing in Portola Pharmaceuticals Inc for a number of months, seems to be bullish on the $3.30B market cap company. The stock decreased 3.51% or $1.87 during the last trading session, reaching $51.42. About 735,146 shares traded. Portola Pharmaceuticals Inc (NASDAQ:PTLA) has risen 51.17% since October 14, 2016 and is uptrending. It has outperformed by 34.47% the S&P500.

Portola Pharmaceuticals Inc (NASDAQ:PTLA) Ratings Coverage

Among 6 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Portola Pharmaceuticals has $81 highest and $24 lowest target. $68.17’s average target is 32.57% above currents $51.42 stock price. Portola Pharmaceuticals had 28 analyst reports since August 5, 2015 according to SRatingsIntel. Oppenheimer maintained the shares of PTLA in report on Thursday, August 10 with “Buy” rating. The firm earned “Neutral” rating on Monday, March 28 by Goldman Sachs. The rating was maintained by Credit Suisse on Wednesday, September 20 with “Buy”. The firm has “Hold” rating given on Thursday, August 10 by Credit Suisse. The company was upgraded on Thursday, August 24 by Credit Suisse. The firm has “Outperform” rating given on Tuesday, December 27 by Credit Suisse. Morgan Stanley maintained the stock with “Overweight” rating in Friday, October 6 report. The firm has “Neutral” rating given on Friday, August 19 by Credit Suisse. The stock of Portola Pharmaceuticals Inc (NASDAQ:PTLA) has “Buy” rating given on Wednesday, August 5 by Cowen & Co. The stock of Portola Pharmaceuticals Inc (NASDAQ:PTLA) has “Overweight” rating given on Friday, August 19 by Morgan Stanley.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $3.30 billion. The Firm is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. It currently has negative earnings. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

More recent Portola Pharmaceuticals Inc (NASDAQ:PTLA) news were published by: Seekingalpha.com which released: “Portola – A High-Risk, High-Return Investment Opportunity” on September 21, 2017. Also Globenewswire.com published the news titled: “Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise …” on October 11, 2017. Seekingalpha.com‘s news article titled: “Expect A Slow Bleed With Portola Pharma” with publication date: September 22, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.